Last reviewed · How we verify
New PEG based artificial tear
PEG-based artificial tear provides lubrication and moisture to the ocular surface to relieve dry eye symptoms.
PEG-based artificial tear provides lubrication and moisture to the ocular surface to relieve dry eye symptoms. Used for Dry eye disease / Keratoconjunctivitis sicca.
At a glance
| Generic name | New PEG based artificial tear |
|---|---|
| Sponsor | Bp Consulting, Inc |
| Drug class | Artificial tear / Lubricating ophthalmic agent |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Polyethylene glycol (PEG) is a hydrophilic polymer that increases tear film viscosity and provides prolonged ocular surface hydration. By forming a protective layer on the cornea and conjunctiva, it reduces friction, maintains moisture, and alleviates symptoms associated with dry eye disease or keratoconjunctivitis sicca.
Approved indications
- Dry eye disease / Keratoconjunctivitis sicca
Common side effects
- Ocular irritation
- Blurred vision
- Eye discomfort
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- New PEG based artificial tear CI brief — competitive landscape report
- New PEG based artificial tear updates RSS · CI watch RSS
- Bp Consulting, Inc portfolio CI